![Aram Andrew Mangasarian](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Aram Andrew Mangasarian
Directeur Général chez TME PHARMA N.V.
Postes actifs de Aram Andrew Mangasarian
Sociétés | Poste | Début | Fin |
---|---|---|---|
TME PHARMA N.V. | Directeur Général | 01/05/2010 | - |
Corporate Officer/Principal | 01/05/2010 | - | |
NOXXON Pharma AG
![]() NOXXON Pharma AG BiotechnologyHealth Technology NOXXON Pharma AG operates a clinical stage biotechnology company. Its core focus is on cancer treatment. The firm offers effectiveness of cancer treatments including immuno-oncology approaches such as immune checkpoint inhibition and current standards of care such as chemotherapy and radiotherapy. The company was founded in 1997 by Sven Klussmann, Jens-Peter Fürste and Thomas Klein and is headquartered in Berlin, Germany. | Directeur/Membre du Conseil | 01/05/2010 | - |
Directeur Général | 01/05/2010 | - | |
Corporate Officer/Principal | 19/05/2010 | 24/07/2015 | |
NOXXON Pharma NV Niederlassung Deutschland
![]() NOXXON Pharma NV Niederlassung Deutschland BiotechnologyHealth Technology NOXXON Pharma NV Niederlassung Deutschland operates as a German biotechnology company. The private company is based in Berlin, Germany. | Directeur/Membre du Conseil | - | - |
Historique de carrière de Aram Andrew Mangasarian
Anciens postes connus de Aram Andrew Mangasarian
Sociétés | Poste | Début | Fin |
---|---|---|---|
ISOFOL MEDICAL AB | Directeur/Membre du Conseil | 01/06/2020 | 01/02/2023 |
Independent Dir/Board Member | 01/06/2020 | 01/02/2023 | |
EUROBIO SCIENTIFIC | Corporate Officer/Principal | - | - |
Exonhit
![]() Exonhit Pharmaceuticals: MajorHealth Technology Exonhit is developing and manufacturing novel pharmaceuticals from its expertise in the field of alternative RNA splicing, the process by which a single gene can lead to several proteins. The firm's proprietary gene profiling technology DATAS is utilized to identify genes whose splice variants produce abnormal proteins which may trigger or contribute to the development of disease. The company was founded in 1997 and is headquartered in Paris, France. | Corporate Officer/Principal | 01/05/2000 | - |
Caerus Consulting AS
![]() Caerus Consulting AS Pharmaceuticals: MajorHealth Technology Caerus Consulting AS engages in the research and development in biotechnology. It develops antibiotics for life threatening bacterial diseases. Its technological core is chemistry on complex molecules. The company was founded by Torgeir Vaage on March 31, 2009 and is headquartered in Hovik, Norway. | Directeur/Membre du Conseil | - | - |
Novexel SA
![]() Novexel SA Pharmaceuticals: MajorHealth Technology Novexel SA researches and develops anti-infective drugs for the treatment of bacterial and fungal infections. The firm focuses on discovery and development of novel antibiotics designed to overcome the significant global problem of microbial resistance. The company was founded in December 2004 and is headquartered in Romainville, France. | Corporate Officer/Principal | 01/10/2005 | - |
Formation de Aram Andrew Mangasarian
University of Wisconsin | Undergraduate Degree |
INSEAD | Masters Business Admin |
University of California San Diego | Doctorate Degree |
Statistiques
Internationale
France | 5 |
Allemagne | 4 |
Etats-Unis | 3 |
Opérationnelle
Corporate Officer/Principal | 5 |
Director/Board Member | 4 |
Chief Executive Officer | 2 |
Sectorielle
Health Technology | 9 |
Consumer Services | 4 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
Sociétés cotées | 3 |
---|---|
ISOFOL MEDICAL AB | Health Technology |
EUROBIO SCIENTIFIC | Health Technology |
TME PHARMA N.V. | Health Technology |
Entreprise privées | 5 |
---|---|
Novexel SA
![]() Novexel SA Pharmaceuticals: MajorHealth Technology Novexel SA researches and develops anti-infective drugs for the treatment of bacterial and fungal infections. The firm focuses on discovery and development of novel antibiotics designed to overcome the significant global problem of microbial resistance. The company was founded in December 2004 and is headquartered in Romainville, France. | Health Technology |
NOXXON Pharma AG
![]() NOXXON Pharma AG BiotechnologyHealth Technology NOXXON Pharma AG operates a clinical stage biotechnology company. Its core focus is on cancer treatment. The firm offers effectiveness of cancer treatments including immuno-oncology approaches such as immune checkpoint inhibition and current standards of care such as chemotherapy and radiotherapy. The company was founded in 1997 by Sven Klussmann, Jens-Peter Fürste and Thomas Klein and is headquartered in Berlin, Germany. | Health Technology |
Exonhit
![]() Exonhit Pharmaceuticals: MajorHealth Technology Exonhit is developing and manufacturing novel pharmaceuticals from its expertise in the field of alternative RNA splicing, the process by which a single gene can lead to several proteins. The firm's proprietary gene profiling technology DATAS is utilized to identify genes whose splice variants produce abnormal proteins which may trigger or contribute to the development of disease. The company was founded in 1997 and is headquartered in Paris, France. | Health Technology |
Caerus Consulting AS
![]() Caerus Consulting AS Pharmaceuticals: MajorHealth Technology Caerus Consulting AS engages in the research and development in biotechnology. It develops antibiotics for life threatening bacterial diseases. Its technological core is chemistry on complex molecules. The company was founded by Torgeir Vaage on March 31, 2009 and is headquartered in Hovik, Norway. | Health Technology |
NOXXON Pharma NV Niederlassung Deutschland
![]() NOXXON Pharma NV Niederlassung Deutschland BiotechnologyHealth Technology NOXXON Pharma NV Niederlassung Deutschland operates as a German biotechnology company. The private company is based in Berlin, Germany. | Health Technology |
- Bourse
- Insiders
- Aram Andrew Mangasarian
- Expérience